Pfizer Inc (PFE.N) plans to complete a review this year of whether it should divest any of its businesses to maximize their value, a top executive at the drugmaker said on Thursday. "We are going through a comprehensive review that we aim to complete during this year," said Mikael Dolsten, Pfizer's president of worldwide research and development. Speaking at a Barclays Capital investor conference, Dolsten said Pfizer Chief Executive Ian Read has said that "we have an innovative core of our company with adjacent businesses, that each of them are doing really well.
Source
